| Recruiting | Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherap NCT07476287 | Pfizer | Phase 2 |
| Not Yet Recruiting | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) NCT07531095 | Amgen | Phase 1 |
| Not Yet Recruiting | SCLC Tarlatamab Blood Collection NCT07468656 | Duke University | — |
| Not Yet Recruiting | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progre NCT07001995 | Hunan Province Tumor Hospital | Phase 2 |
| Not Yet Recruiting | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of C NCT07365241 | AbbVie | Phase 3 |
| Recruiting | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors NCT07424547 | Conjupro Biotherapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in P NCT07231445 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 |
| Not Yet Recruiting | SYS6090 Combination Therapy in Advanced Lung Cancer NCT07472647 | Shanghai JMT-Bio Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Sma NCT07398560 | The Third Affiliated Hospital of Harbin Medical University | Phase 2 |
| Not Yet Recruiting | Tarlatamab for SCLC Brain Metastases NCT07402343 | Maastricht University Medical Center | Phase 2 |
| Recruiting | SKB500 Combinations in Patients With Small Cell Lung Cancer NCT07296809 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With NCT07376499 | China Medical University, China | Phase 2 |
| Not Yet Recruiting | A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Can NCT07253142 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) NCT07155200 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Recruiting | Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Ca NCT07189455 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 |
| Recruiting | ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer NCT06922539 | SciTech Development, Inc. | Phase 1 |
| Recruiting | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cance NCT07218146 | Zai Lab (Shanghai) Co., Ltd. | Phase 3 |
| Recruiting | A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in NCT07155174 | AbbVie | Phase 2 |
| Recruiting | 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCL NCT07175077 | University of Missouri-Columbia | — |
| Recruiting | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors NCT07208773 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of DXC014 in Patients With Advanced Solid Tumors. NCT07177937 | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combin NCT07373964 | China Medical University, China | Phase 2 |
| Recruiting | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer NCT07174583 | IDEAYA Biosciences | Phase 1 / Phase 2 |
| Not Yet Recruiting | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy NCT07076914 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Recruiting | ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma NCT07038096 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | DESTINY-PANTUMOUR04 NCT07124000 | AstraZeneca | — |
| Not Yet Recruiting | A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors NCT07173244 | Tianjin First Central Hospital | — |
| Not Yet Recruiting | Prospective Observational Study on ES-SCLC NCT07173946 | Peking Union Medical College Hospital | — |
| Not Yet Recruiting | A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherap NCT07069270 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etopo NCT07005128 | Amgen | Phase 3 |
| Recruiting | Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer NCT06931626 | Nerviano Medical Sciences | Phase 1 |
| Completed | Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC) NCT07050472 | Anhui Shi, MD | — |
| Not Yet Recruiting | A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Can NCT07076095 | SUNHO（China）BioPharmaceutical CO., Ltd. | Phase 2 |
| Not Yet Recruiting | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer NCT07110363 | Biotroy Therapeutics | Phase 1 |
| Active Not Recruiting | Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms NCT01064466 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Phase 2 / Phase 3 |
| Recruiting | Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518 | GV20 Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have No NCT07010263 | Akeso | Phase 3 |
| Not Yet Recruiting | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Adva NCT07004712 | Peking University Cancer Hospital & Institute | Phase 2 |
| Recruiting | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer NCT07508852 | Peking University First Hospital | Phase 1 / Phase 2 |
| Recruiting | Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies NCT06486428 | Addario Lung Cancer Medical Institute | — |
| Recruiting | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Partic NCT06898957 | Amgen | Phase 1 |
| Recruiting | Phase 2 Study of Fingolimod in Lung Cancers NCT06424067 | Medical University of South Carolina | Phase 2 |
| Not Yet Recruiting | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With NCT06951841 | China Medical University, China | Phase 4 |
| Recruiting | A Study of Hospital-at-Home for People Receiving Tarlatamab NCT06957314 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors NCT06970795 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1 |
| Recruiting | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer NCT06592638 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Partic NCT06780137 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer NCT06840704 | Hunan Cancer Hospital | Phase 3 |
| Completed | A Study of AL8326 in Healthy Subjects NCT07132957 | Advenchen Laboratories Nanjing Ltd. | Phase 1 |
| Recruiting | Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) NCT06717243 | Oncology Center of Biochemical Education And Research | — |
| Recruiting | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known NCT06805825 | Novelty Nobility, Inc. | Phase 1 |
| Not Yet Recruiting | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. NCT06789796 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC NCT06769971 | Sichuan University | Phase 2 |
| Recruiting | A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell NCT07026669 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer NCT06613009 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Recruiting | A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer NCT06612151 | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 3 |
| Enrolling By Invitation | INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer NCT06747832 | Guangzhou Ruixin Biotechnological Co., LTD | EARLY_Phase 1 |
| Not Yet Recruiting | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in t NCT06724263 | Tasly Biopharmaceuticals Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic NCT06497543 | Hunan Province Tumor Hospital | Phase 2 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer NCT06581380 | JenKem Technology Co., Ltd. | Phase 3 |
| Recruiting | A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumor NCT06873555 | Heronova Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinom NCT06283719 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer NCT06480864 | Yunpeng Liu | N/A |
| Active Not Recruiting | A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) NCT06500026 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Canc NCT06449209 | BioNTech SE | Phase 2 |
| Recruiting | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tum NCT06505824 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer NCT06462105 | Zhou Chengzhi | N/A |
| Recruiting | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer NCT06498479 | Hansoh BioMedical R&D Company | Phase 3 |
| Recruiting | Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer NCT06527898 | Anhui Provincial Hospital | Phase 1 / Phase 2 |
| Completed | MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy NCT07489339 | Shanxi Province Cancer Hospital | N/A |
| Active Not Recruiting | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lun NCT06211036 | Amgen | Phase 3 |
| Recruiting | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell L NCT06203210 | Daiichi Sankyo | Phase 3 |
| Recruiting | Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cance NCT06514118 | Qingdao Central Hospital | — |
| Recruiting | Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer NCT06406660 | Henan Cancer Hospital | N/A |
| Recruiting | Serplulimab Combined With CCRT for LS-SCLC. NCT06295926 | Peking Union Medical College Hospital | Phase 2 |
| Not Yet Recruiting | Examining Clinical Trial Participation for Small Cell Lung Cancer Patients NCT05769504 | Power Life Sciences Inc. | — |
| Not Yet Recruiting | Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC NCT06364046 | The Central Hospital of Lishui City | N/A |
| Recruiting | Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer NCT06467786 | Tang-Du Hospital | Phase 4 |
| Recruiting | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors NCT06257264 | BeiGene | Phase 1 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) NCT06117774 | Amgen | Phase 3 |
| Recruiting | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer NCT06095505 | Puma Biotechnology, Inc. | Phase 2 |
| Enrolling By Invitation | Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC NCT06816966 | Fujian Medical University Union Hospital | Phase 2 |
| Recruiting | TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO NCT05628376 | University College, London | — |
| Recruiting | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer NCT05924841 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis NCT06160596 | Cure 51 | — |
| Recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Meta NCT06047379 | Neonc Technologies, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma NCT05978284 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE) NCT06103682 | University of California, Davis | N/A |
| Withdrawn | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer NCT05572476 | Institut Bergonié | Phase 2 |
| Active Not Recruiting | The Predictive Value of Proteome Profiling for Brain Metastasis in Limited-Stage Small-Cell Lung Cancer NCT06483919 | Jinming Yu | — |
| Suspended | MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer NCT05903092 | Hirva Mamdani | Phase 2 |
| Recruiting | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors W NCT06022757 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC NCT06457906 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 |
| Recruiting | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Sol NCT05983432 | SystImmune Inc. | Phase 1 |
| Active Not Recruiting | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunother NCT05703269 | Wake Forest University Health Sciences | N/A |
| Recruiting | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Tre NCT05957510 | Guangdong Association of Clinical Trials | Phase 2 |
| Terminated | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and NCT05551117 | MacroGenics | Phase 2 |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Recruiting | JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer NCT04951947 | Hunan Province Tumor Hospital | Phase 2 |
| Not Yet Recruiting | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Ca NCT05882630 | Fujian Cancer Hospital | Phase 1 / Phase 2 |
| Unknown | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 NCT05829057 | Zhejiang University | Phase 1 |
| Recruiting | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies NCT05783622 | Janux Therapeutics | Phase 1 |
| Active Not Recruiting | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small C NCT05616624 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Withdrawn | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer NCT05411679 | Ellipses Pharma | Phase 2 |
| Unknown | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid T NCT05886075 | Shanghai Yunying Medical Technology | EARLY_Phase 1 |
| Unknown | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive S NCT05354700 | Shanghai Henlius Biotech | Phase 2 |
| Active Not Recruiting | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subj NCT05827614 | Boundless Bio, Inc. | Phase 1 |
| Unknown | IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors NCT05780307 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 |
| Recruiting | Proteomics in Small Cell Lung Cancer NCT05623956 | Aalborg University Hospital | — |
| Terminated | Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolat NCT05049863 | Washington University School of Medicine | Phase 1 |
| Unknown | SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) NCT05731518 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer NCT05800587 | Fox Chase Cancer Center | Phase 2 |
| Completed | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activ NCT05619744 | Hoffmann-La Roche | Phase 1 |
| Terminated | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET NCT05420636 | Fox Chase Cancer Center | Phase 2 |
| Unknown | Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer NCT05595889 | Fujian Cancer Hospital | Phase 2 |
| Completed | CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer NCT07316309 | Shandong Cancer Hospital and Institute | — |
| Active Not Recruiting | Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC NCT05363280 | Advenchen Pharmaceuticals, LLC. | Phase 2 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Recruiting | Study of Trilaciclib and Lurbinectidin NCT05578326 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer NCT05797493 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Unknown | Immunological Variables Associated to ICI Toxicity in Cancer Patients NCT05429866 | Jules Bordet Institute | Phase 2 |
| Recruiting | Rapid Autopsy Protocol for Patients With Small Cell Lung Cancer NCT05889546 | Indiana University | — |
| Recruiting | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. NCT05271292 | Chipscreen Biosciences, Ltd. | Phase 1 / Phase 2 |
| Recruiting | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) NCT05068232 | University of Chicago | Phase 2 |
| Suspended | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers NCT05337735 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Mass Balance Study of [14C]Chiauranib NCT05371899 | Chipscreen Biosciences, Ltd. | N/A |
| Recruiting | Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer NCT05450965 | University of Maryland, Baltimore | Phase 2 |
| Recruiting | TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor) NCT05257551 | Tempus AI | — |
| Recruiting | Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer NCT04952480 | AHS Cancer Control Alberta | Phase 2 |
| Recruiting | A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain NCT05419076 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients NCT05253053 | TransThera Sciences (Nanjing), Inc. | Phase 1 / Phase 2 |
| Completed | RW Effectiveness of Lurbinectedin in Extensive Stage SCLC NCT05285033 | Intergroupe Francophone de Cancerologie Thoracique | — |
| Completed | A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China NCT05337163 | Creative Biosciences (Guangzhou) Co., Ltd. | — |
| Terminated | Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer NCT05223647 | Norwegian University of Science and Technology | Phase 3 |
| Recruiting | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab NCT06771518 | Regina Elena Cancer Institute | Phase 2 |
| Terminated | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer NCT05027867 | Kartos Therapeutics, Inc. | Phase 2 |
| Unknown | Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer NCT05296603 | Hunan Province Tumor Hospital | Phase 2 |
| Active Not Recruiting | DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS NCT05254119 | Mahmut Gumus | — |
| Active Not Recruiting | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atez NCT05091567 | Hoffmann-La Roche | Phase 3 |
| Unknown | Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy NCT04985201 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Unknown | Circulating EV Long RNA Profiles in SCLC NCT05191849 | Fudan University | N/A |
| Completed | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) NCT04885998 | Amgen | Phase 1 |
| Terminated | Liver Directed RT + Chemo-immunotherapy for ES-SCLC NCT04923776 | Brian Henick, MD | Phase 2 |
| Unknown | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese NCT05245994 | Li Zhang, MD | Phase 2 |
| Unknown | Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy NCT04698941 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Completed | Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Lin NCT04924101 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Ce NCT04951115 | Weill Medical College of Cornell University | Phase 2 |
| Withdrawn | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors NCT04841538 | Elpiscience Biopharma, Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Ca NCT04870112 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab i NCT04472949 | Swiss Cancer Institute | Phase 2 |
| Completed | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) NCT04834778 | HiberCell, Inc. | Phase 1 |
| Terminated | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Ce NCT04590781 | Xencor, Inc. | Phase 1 / Phase 2 |
| Unknown | Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer NCT04782089 | Qilu Hospital of Shandong University | N/A |
| Unknown | Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-C NCT04542369 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Unknown | Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC NCT04683198 | Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer NCT05761977 | Hellenic Cooperative Oncology Group | — |
| Completed | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) NCT04768296 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Terminated | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid NCT04272034 | Incyte Corporation | Phase 1 |
| Completed | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid NCT04742959 | TransThera Sciences (Nanjing), Inc. | Phase 1 / Phase 2 |
| Terminated | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors NCT04579757 | Hutchmed | Phase 1 / Phase 2 |
| Completed | Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer NCT04830813 | Chipscreen Biosciences, Ltd. | Phase 3 |
| Active Not Recruiting | TH1902 in Patients With Advanced Solid Tumors NCT04706962 | Theratechnologies | Phase 1 |
| Unknown | Effect of Combination Therapy on SCLC After Initial Treatment Failure NCT04790955 | First Affiliated Hospital of Harbin Medical University | — |
| Active Not Recruiting | Study of AZD2811 + Durvalumab in ES-SCLC NCT04745689 | AstraZeneca | Phase 2 |
| Completed | Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC NCT04920981 | Intergroupe Francophone de Cancerologie Thoracique | — |
| Recruiting | Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy NCT05552846 | Ruijin Hospital | N/A |
| Completed | Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of P NCT05001971 | Hunan Cancer Hospital | Phase 2 |
| Unknown | The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radioth NCT04691063 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Terminated | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, NCT04610684 | Jeffrey Clarke | Phase 2 |
| Unknown | Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Smal NCT04696939 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Active Not Recruiting | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) NCT04471727 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 / Phase 2 |
| Active Not Recruiting | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab an NCT04624204 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer NCT04740021 | Taizhou HoudeAoke Biomedical Co., Ltd. | Phase 2 |
| Terminated | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC NCT04610658 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy NCT04596033 | Genocea Biosciences, Inc. | Phase 1 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients Wi NCT04640480 | SN BioScience | Phase 1 |
| Unknown | A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer NCT04890795 | Advenchen Laboratories Nanjing Ltd. | Phase 1 / Phase 2 |
| Recruiting | Talazoparib and Thoracic RT for ES-SCLC NCT04170946 | University Health Network, Toronto | Phase 1 |
| Unknown | A Study of Gimatecan (ST1481) in Small Cell Lung Cancer NCT04501029 | Lee's Pharmaceutical Limited | Phase 2 |
| Completed | Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer NCT04381910 | Luye Pharma Group Ltd. | Phase 2 |
| Terminated | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With NCT04422210 | Hoffmann-La Roche | Phase 1 |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | PF-07104091 as a Single Agent and in Combination Therapy NCT04553133 | Pfizer | Phase 2 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid NCT04242199 | Incyte Corporation | Phase 1 |
| Recruiting | PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer NCT04539977 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Terminated | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer NCT04210037 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Completed | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours NCT04504669 | AstraZeneca | Phase 1 |
| Completed | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer NCT04434482 | Impact Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance NCT04450043 | Massachusetts General Hospital | N/A |
| Unknown | Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. NCT04490421 | Fuzhou General Hospital | Phase 3 |
| Unknown | A Real-world Study of Durvalumab for Lung Cancer in China NCT04672759 | Peking Union Medical College Hospital | — |
| Completed | eRAPID: Online Symptom Reporting in Lung Cancer NCT04324437 | University of Leeds | N/A |
| Completed | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung C NCT04730999 | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 2 |
| Terminated | A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy NCT04352413 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Completed | Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects NCT04361825 | Se-Hoon Lee | Phase 2 |
| Completed | A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed NCT04400188 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Completed | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors NCT04332653 | NeoImmuneTech | Phase 1 / Phase 2 |
| Completed | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers NCT04209595 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemot NCT04314297 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer NCT04342429 | Emory University | N/A |
| Active Not Recruiting | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (K NCT04152499 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Recruiting | A Multicenter Cancer Biospecimen Collection Study NCT04510129 | Cofactor Genomics, Inc. | — |
| Completed | A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated NCT04256421 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors NCT04247126 | Syros Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC NCT04010357 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | LITT and Pembrolizumab in Recurrent Brain Metastasis NCT04187872 | University of Florida | Phase 1 |
| Terminated | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer NCT04173325 | Augusta University | Phase 1 |
| Recruiting | PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 NCT04199741 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Closed vs. Open Face Masks for Cranial Radiotherapy NCT04079595 | University of Zurich | N/A |
| Terminated | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors NCT04116320 | Craig L Slingluff, Jr | Phase 1 |
| Unknown | Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis NCT04171986 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Recruiting | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers NCT06255197 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Unknown | Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer NCT04073550 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Active Not Recruiting | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors NCT04165330 | Sarcoma Oncology Research Center, LLC | Phase 1 / Phase 2 |
| Terminated | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors NCT04032704 | Seagen Inc. | Phase 2 |
| Completed | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors NCT03997968 | Cyteir Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer NCT04128800 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers NCT03761914 | Sellas Life Sciences Group | Phase 1 / Phase 2 |
| Unknown | CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) NCT03904719 | AnewPharma | Phase 2 |
| Completed | A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients NCT04041011 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma NCT03958045 | Zhonglin Hao | Phase 2 |
| Terminated | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) NCT04022876 | Aileron Therapeutics, Inc. | Phase 1 |
| Unknown | Watchful Observation of Patients With LD-SCLC Instead of the PCI NCT04168281 | Sergiusz Nawrocki | N/A |
| Unknown | Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC NCT03994744 | Hunan Cancer Hospital | Phase 2 |
| Terminated | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Terminated | Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain NCT03488472 | Drexell Hunter Boggs | N/A |
| Recruiting | Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in NCT03467360 | Centre Antoine Lacassagne | Phase 1 |
| Completed | Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer NCT04012606 | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 |
| Completed | Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage S NCT04005716 | BeiGene | Phase 3 |
| Completed | A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer NCT03898791 | Eli Lilly and Company | Phase 1 |
| Unknown | PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study NCT04535739 | Chinese Academy of Medical Sciences | Phase 3 |
| Unknown | Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer NCT03983759 | Henan Cancer Hospital | Phase 2 |
| Terminated | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumor NCT04234113 | SOTIO Biotech AG | Phase 1 |
| Terminated | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular I NCT04106167 | Fate Therapeutics | — |
| Completed | Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer NCT03913455 | Shadia Jalal, MD | Phase 2 |
| Active Not Recruiting | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer NCT03923270 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors NCT03881488 | Compass Therapeutics | Phase 1 |
| Unknown | Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer NCT04192682 | Changzhou Cancer Hospital of Soochow University | Phase 2 / Phase 3 |
| Completed | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398 | Xencor, Inc. | Phase 1 |
| Unknown | Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride NCT03890055 | Chifeng Municipal Hospital | Phase 4 |
| Unknown | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor NCT03896958 | SpeciCare | — |
| Terminated | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer NCT03879798 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumo NCT03841110 | Fate Therapeutics | Phase 1 |
| Active Not Recruiting | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated NCT03782207 | Hoffmann-La Roche | — |
| Unknown | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors NCT03734913 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC NCT03780283 | First Hospital of Shijiazhuang City | Phase 2 |
| Active Not Recruiting | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advance NCT03728361 | Dwight Owen | Phase 2 |
| Active Not Recruiting | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Im NCT03228667 | ImmunityBio, Inc. | Phase 2 |
| Active Not Recruiting | Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Ch NCT03670056 | Yale University | Phase 2 |
| Unknown | PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy NCT03776604 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | N/A |
| Completed | A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refr NCT03639194 | AbbVie | Phase 1 |
| Unknown | Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lun NCT04731909 | Third Military Medical University | N/A |
| Unknown | Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and NCT03523234 | Peng Zhang | N/A |
| Active Not Recruiting | Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patient NCT03703297 | AstraZeneca | Phase 3 |
| Completed | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077 | Incyte Corporation | Phase 1 |
| Completed | M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers NCT03554473 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Suspended | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC NCT03392064 | Amgen | Phase 1 |
| Unknown | Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer NCT03651219 | Beijing Chest Hospital | Phase 3 |
| Unknown | Clinical Study of Combined Radical Operation With Postoperative Adjuvant Chemotherapy and Prophylactic Cranial NCT03514849 | Peng Zhang | N/A |
| Active Not Recruiting | Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell NCT03540420 | Norwegian University of Science and Technology | Phase 2 |
| Completed | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer NCT03532880 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | DOTATOC PET/CT for Imaging NET Patients NCT03583528 | British Columbia Cancer Agency | — |
| Completed | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors NCT03583086 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Terminated | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor NCT03724253 | Advanced Accelerator Applications | Phase 2 |
| Unknown | Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer NCT03585998 | Samsung Medical Center | Phase 2 |
| Unknown | Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer NCT03613597 | Guizhou Medical University | Phase 2 |
| Unknown | Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer NCT03613753 | ShengFa Su | Phase 2 |
| Completed | A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Pat NCT03547804 | The First Hospital of Jilin University | Phase 2 |
| Completed | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer NCT03088813 | Ipsen | Phase 3 |
| Completed | SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy NCT03417895 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Unknown | NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer. NCT03410368 | jiuwei cui | Phase 2 |
| Withdrawn | Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Rel NCT03334487 | AbbVie | Phase 3 |
| Terminated | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer ( NCT03406715 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases NCT03391362 | Dana-Farber Cancer Institute | N/A |
| Completed | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies NCT03365791 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer NCT03371979 | Aeglea Biotherapeutics | Phase 1 / Phase 2 |
| Terminated | AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] NCT03366675 | Samsung Medical Center | Phase 2 |
| Unknown | Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer NCT03389087 | Henan Cancer Hospital | Phase 2 |
| Completed | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer NCT03325816 | Georgetown University | Phase 1 / Phase 2 |
| Completed | Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer NCT03216343 | Chipscreen Biosciences, Ltd. | Phase 1 |
| Completed | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. NCT03345485 | Mundipharma Research Limited | Phase 1 / Phase 2 |
| Completed | A Study of PLX2853 in Advanced Malignancies. NCT03297424 | Opna Bio LLC | Phase 1 |
| Completed | Bioinformation Therapy for Lung Cancer NCT03239171 | Fuda Cancer Hospital, Guangzhou | Phase 2 / Phase 3 |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms NCT03219268 | MacroGenics | Phase 1 |
| Terminated | Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification NCT03106155 | Samsung Medical Center | Phase 2 |
| Unknown | Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer NCT04500145 | Chinese Academy of Medical Sciences | Phase 3 |
| Completed | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive NCT03041311 | G1 Therapeutics, Inc. | Phase 2 |
| Completed | TS Overexpression in SCLC: Mechanism and Therapeutic Targeting NCT03741829 | Wake Forest University Health Sciences | — |
| Completed | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases NCT02978404 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Completed | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Can NCT03098030 | United Therapeutics | Phase 2 / Phase 3 |
| Terminated | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED NCT03116971 | EMD Serono Research & Development Institute, Inc. | Phase 1 |
| Terminated | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer NCT02963090 | Alliance Foundation Trials, LLC. | Phase 2 |
| Unknown | Molecular Profiling in Small Cell Lung Cancer NCT03162705 | Zhujiang Hospital | — |
| Completed | A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurren NCT03086239 | AbbVie | Phase 1 |